Lock and security products developer Starcom believes that it can still meet revenue expectations for this year even though a client has failed to order the contracted product volumes.
The Starcom share price fell 0.05p to 1.25p.
Xplosive Solutions had already revised the original agreement to sell Kylos units for the protection of cattle. The original agreement was announced in October 2017, but technical problems delayed revenues. In February, it was agreed that over a period of 36 months, Xplosive would pay a monthly fee for each Kylos unit.
This was expected to generate $500,000 over three years, but only a limited number of units were shipped. Starcom claims that Xplosive is unwilling or unable to continue because of local reason and the contract has been terminated.
Full year revenues were expected to grow by 11% to £6.7m and there was even the chance of Starcom making a small profit. The interims are coming up and they will provide some indication of the progress towards that target.
© 2019 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Omega Diagnostics will lose money this year, but it is on course to become profitable in 2020-21 as sales of the VISITECT CD4 test.
House broker Shore Capital has slashed its pre-tax profit forecast for engineer Tricorn Group by two-thirds to £420,000.
Evgen Pharma has entered into an agreement with The University of Dundee for the use of SFX-01 in a clinical trial in non-alcoholic steatohepatitis and liver fibrosis, where there is no existing treatment.